GLP-1 Therapies

Novo Nordisk Narrows Gap With Lilly as Wegovy Pill Leads Early Oral Sales

Stronger early prescriptions for the earlier-launched pill have refocused investor debate over which maker can turn GLP-1 demand into sustained revenue.